[1]周立莉,周冬霞,徐寿华,等.多疗程DC-CIK免疫疗法治疗晚期肺癌的临床疗效[J].医学信息,2019,(20):5-8.[doi:10.3969/j.issn.1006-1959.2019.20.002]
 ZHOU Li-li,ZHOU Dong-xia,XU Shou-hua,et al.Clinical Efficacy of Multiple Courses of DC-CIK Immunotherapy in the Treatment of Advanced Lung Cancer[J].Medical Information,2019,(20):5-8.[doi:10.3969/j.issn.1006-1959.2019.20.002]
点击复制

多疗程DC-CIK免疫疗法治疗晚期肺癌的临床疗效()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年20期
页码:
5-8
栏目:
肺癌与肺损伤专题
出版日期:
2019-10-15

文章信息/Info

Title:
Clinical Efficacy of Multiple Courses of DC-CIK Immunotherapy in the Treatment of Advanced Lung Cancer
文章编号:
1006-1959(2019)20-0005-04
作者:
周立莉1周冬霞1徐寿华1吴金芸2蔡茂怀1
(1.江苏省盐城市第二人民医院肿瘤内科,江苏 盐城 224000;2.伯仕利生物科技发展<盐城>有限公司,江苏 盐城 224000)
Author(s):
ZHOU Li-li1ZHOU Dong-xia1XU Shou-hua1WU Jin-yun2CAI Mao-huai1
(1.Department of Oncology,the Second People's Hospital of Yancheng,Yancheng 224000,Jiangsu,China;2.Bursley Biotechnology DevelopmentCo.Ltd.,Yancheng 224000,Jiangsu,China)
关键词:
DC-CIK肺癌免疫疗法多疗程
Keywords:
DC-CIKLung cancerImmunotherapyMultiple courses
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.20.002
文献标志码:
A
摘要:
目的 观察多疗程DC-CIK治疗晚期肺癌的临床疗效。方法 选取2014年12月~2018年12月我院收治的化疗后肺癌患者86例,采用随机数字表法分为对照组和实验组,各43例。对照组行1个疗程DC-CIK治疗,实验组行3个疗程以上的DC-CIK治疗。比较两组治疗后疗效、淋巴细胞水平、细胞因子水平、肿瘤标志物表达以及不良反应发生情况。结果 实验组疾病控制率(69.77%)高于对照组(41.86%)。治疗后两组CD4+、CD4+/CD8+、NK表达均较治疗前升高,且实验组高于对照组(P<0.05);治疗后两组CD8+表达均较治疗前下降,且实验组低于对照组(P<0.05);两组治疗前后IL-4、IL-6、IL-10无明显变化(P>0.05);治疗后两组IL-2、TNF-α、IFN-γ均较治疗前升高,且随着治疗次数增加,IL-2、TNF-α、IFN-γ逐渐升高(P<0.05);治疗后两组AFP、NSE、CYfra21-1均较治疗前下降(P<0.05);两组第一次治疗后CEA升高(P<0.05);实验组末次治疗后,CEA下降(P<0.05);两组均未出现不良反应。结论 多疗程DC-CIK免疫疗法治疗晚期肺癌临床疗效确切,能有效清除肿瘤细胞,且安全无副作用。
Abstract:
Objective To observe the clinical efficacy of multi-course DC-CIK in the treatment of advanced lung cancer. Methods 86 patients with lung cancer after chemotherapy from December 2014 to December 2018 were enrolled. The patients were divided into the control group and the experimental group by random number table, 43 cases each. The control group received one course of DC-CIK treatment, and the experimental group received three courses of DC-CIK treatment. The therapeutic effects, lymphocyte levels, cytokine levels, tumor marker expression, and adverse reactions were compared between the two groups.Results The disease control rate (69.77%) in the experimental group was higher than that in the control group (41.86%). The expressions of CD4+,CD4+/CD8+ and NK in the two groups were higher than those before treatment, and the experimental group was higher than the control group (P<0.05).The expression of CD8+ in the two groups decreased after treatment, and the experimental group was lower than the control group (P<0.05). There was no significant change in IL-4, IL-6 and IL-10 before and after treatment (P>0.05). The latter two groups of IL-2, TNF-α, IFN-γ were higher than before treatment, and with the increase of treatment times, IL-2, TNF-α, IFN-γ increased gradually(P<0.05).After treatment, AFP, NSE and CYfra21-1 were lower than those before treatment(P<0.05); CEA increased after the first treatment in both groups (P<0.05); CEA decreased after the last treatment in the experimental group(P<0.05); no adverse reactions occurred in either group.Conclusion Multi-course DC-CIK immunotherapy is effective in the treatment of advanced lung cancer. It can effectively remove tumor cells and has no side effects.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Heather Wakelee.50 Years of Progress in the Systemic Therapy of Non-Small Cell Lung Cancer[J].Am Soc Clin Oncol Educ Book,2014:177-89. [3]Hirsch FR,Scagliotti GV,Mulshine JL,et al.Lung cancer:current therapies and new targeted treatments[J].Lancet,2017,389(10066):299-311. [4]吴军,杨小平.分子靶向药物治疗非小细胞肺癌的研究进展[J].医学理论与实践,2019, 32(10):1489-1490. [5]Ren PT,Zhang Y.Comparative investigation of the effects of specific antigen?sensitized DC-CIK and DC-CTL cells against B16 melanoma tumor cells[J].Mol Med Rep,2017,15(4):1533-1538. [6]人体细胞治疗研究和制剂质量控制技术指导原则(国家食药监督局文件), http://samr.cfda.gov.cn/WS01/CL0237/15709.html [7]Gao D,Li C,Xie X,et al.Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients[J].PLoS One,2014,9(4):e93886. [8]韦庄怡,任小朋,王博.DC-CIK自体回输对化疗后胃癌患者T淋巴细胞亚群及NK细胞的影响[J].临床和实验医学杂志,2019,18(11):1179-1182. [9]单海霞,黄广清.DC-CIK联合化疗治疗进展期胃癌45例的临床疗效评价[J].胃肠病学和肝病学杂志,2014,23(12):1416-1419. [10]王金烁,谢泽新,李慧杰.DC-CIK联合化疗治疗晚期胃癌的近期疗效[J].实用肿瘤杂志,2016,31(1):38-42. [11]吴有军,曹志宇,张庆军.DC-CIK对结直肠癌根治术后肝转移患者疗效和循环肿瘤细胞的影响[J].中国肿瘤生物治疗杂志,2018,25(1):89-93. [12]Mai HX,Mei GH,Zhao FL,et al.Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy[J].Cancer Res Ther,2018,14(Supplement):S427-S432. [13]Qin W,Xiong Y,Chen J,et al.DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells[J].Cell Mol Med,2018,22(7):3364-3376. [14]Hu J,Hu J,Liu X,et al.Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer[J]. Medicine,2017,96(42):e8310. [15]Xiao X,Ye X,Xu C,et al.Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen[J].Onco Targets Ther,2018,29(11):7555-7558. [16]Dhupkar P,Gordon N.Interleukin-2:Old and New Approaches to Enhance Immune-Therapeutic Efficacy[J].Adv Exp Med Biol,2017(995):33-51. [17]Gong W,Hoffmann JM,Stock S,et al.Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells[J].Cancer Immunol Immunother,2019,68(7):1195-1209. [18]Wang L,Wang Y,Song Z,et al.Interferon Cytokine Res[J]. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development,2015,35(4):273-280.

相似文献/References:

[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
 YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Medical Information,2018,(20):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹晓美,王莉娜.肺癌患者疾病不确定感的影响因素与干预措施研究现状[J].医学信息,2018,(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
 DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Medical Information,2018,(20):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]邢益辉,刘 曼,厉玛倩倩,等.快速康复对肺癌手术患者并发症发生及生活质量的影响研究[J].医学信息,2018,(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
 XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Medical Information,2018,(20):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[4]朱晓晓,张 顺,蔡 挺.镍暴露相关的肺癌发生分子机制研究[J].医学信息,2018,(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
 ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Medical Information,2018,(20):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[5]付云杰.肺癌患者血浆D-二聚体、NSE及CYFRA21-1联合检测的临床价值[J].医学信息,2018,(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
 FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Medical Information,2018,(20):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[6]覃柳麻,何慧敏.2014~2016年广西肿瘤医院肺癌患者流行病学及病理分布特征分析[J].医学信息,2019,(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
 QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Medical Information,2019,(20):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[7]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
 WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Medical Information,2019,(20):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[8]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
 YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Medical Information,2019,(20):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
[9]郭 磊,王小文,向小勇.中性粒细胞与淋巴细胞比值与肺癌预后关系研究[J].医学信息,2019,(09):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
 GUO Lei,WANG Xiao-wen,XIANG Xiao-yong.Relationship between Neutrophil-lymphocyte Ratio and Prognosis of Lung Cancer[J].Medical Information,2019,(20):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
[10]王 猛.循环肿瘤细胞在肺癌诊疗中的临床研究进展[J].医学信息,2019,(15):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]
 WANG Meng.Progress in Clinical Research of Circulating Tumor Cells in the Diagnosis and Treatment of Lung Cancer[J].Medical Information,2019,(20):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]

更新日期/Last Update: 2019-10-15